List of Excipients in API calcipotriene and betamethasone dipropionate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing calcipotriene and betamethasone dipropionate
Excipients in ANDA-approved (generic) drugs containing calcipotriene and betamethasone dipropionate
Detailed excipient profiles for calcipotriene and betamethasone dipropionate
Excipient focus: .ALPHA.-TOCOPHEROL, DL-
calcipotriene and betamethasone dipropionate drug variants containing .ALPHA.-TOCOPHEROL, DL-
calcipotriene and betamethasone dipropionate drug variants not containing .ALPHA.-TOCOPHEROL, DL-
Excipient focus: ALPHA-TOCOPHEROL, DL-
calcipotriene and betamethasone dipropionate drug variants containing ALPHA-TOCOPHEROL, DL-
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | calcipotriene and betamethasone dipropionate | 54868-5680 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing ALPHA-TOCOPHEROL, DL-
Excipient focus: BUTANE
calcipotriene and betamethasone dipropionate drug variants containing BUTANE
| Company | Ingredient | NDC |
|---|---|---|
| LEO Pharma Inc | calcipotriene and betamethasone dipropionate | 50222-302 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing BUTANE
Excipient focus: BUTYLATED HYDROXYANISOLE
calcipotriene and betamethasone dipropionate drug variants containing BUTYLATED HYDROXYANISOLE
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing BUTYLATED HYDROXYANISOLE
Excipient focus: BUTYLATED HYDROXYTOLUENE
calcipotriene and betamethasone dipropionate drug variants containing BUTYLATED HYDROXYTOLUENE
calcipotriene and betamethasone dipropionate drug variants not containing BUTYLATED HYDROXYTOLUENE
Excipient focus: CARBOMER INTERPOLYMER TYPE A
calcipotriene and betamethasone dipropionate drug variants containing CARBOMER INTERPOLYMER TYPE A
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing CARBOMER INTERPOLYMER TYPE A
Excipient focus: DIAZOLIDINYL UREA
calcipotriene and betamethasone dipropionate drug variants containing DIAZOLIDINYL UREA
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | calcipotriene and betamethasone dipropionate | 0781-7165 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing DIAZOLIDINYL UREA
Excipient focus: DIMETHYL ETHER
calcipotriene and betamethasone dipropionate drug variants containing DIMETHYL ETHER
| Company | Ingredient | NDC |
|---|---|---|
| LEO Pharma Inc | calcipotriene and betamethasone dipropionate | 50222-302 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing DIMETHYL ETHER
Excipient focus: HYDROGENATED CASTOR OIL
calcipotriene and betamethasone dipropionate drug variants containing HYDROGENATED CASTOR OIL
calcipotriene and betamethasone dipropionate drug variants not containing HYDROGENATED CASTOR OIL
Excipient focus: ISOPROPYL ALCOHOL
calcipotriene and betamethasone dipropionate drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing ISOPROPYL ALCOHOL
Excipient focus: ISOPROPYL MYRISTATE
calcipotriene and betamethasone dipropionate drug variants containing ISOPROPYL MYRISTATE
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing ISOPROPYL MYRISTATE
Excipient focus: LAURETH-4
calcipotriene and betamethasone dipropionate drug variants containing LAURETH-4
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing LAURETH-4
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
calcipotriene and betamethasone dipropionate drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | calcipotriene and betamethasone dipropionate | 0781-7165 |
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
Excipient focus: MINERAL OIL
calcipotriene and betamethasone dipropionate drug variants containing MINERAL OIL
calcipotriene and betamethasone dipropionate drug variants not containing MINERAL OIL
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | calcipotriene and betamethasone dipropionate | 0781-7165 |
| >Company | >Ingredient | >NDC |
Excipient focus: PETROLATUM
calcipotriene and betamethasone dipropionate drug variants containing PETROLATUM
calcipotriene and betamethasone dipropionate drug variants not containing PETROLATUM
Excipient focus: POLOXAMER 407
calcipotriene and betamethasone dipropionate drug variants containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing POLOXAMER 407
Excipient focus: POLYOXYL 40 HYDROGENATED CASTOR OIL
calcipotriene and betamethasone dipropionate drug variants containing POLYOXYL 40 HYDROGENATED CASTOR OIL
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing POLYOXYL 40 HYDROGENATED CASTOR OIL
Excipient focus: POLYPROPYLENE GLYCOL 11 STEARYL ETHER
calcipotriene and betamethasone dipropionate drug variants containing POLYPROPYLENE GLYCOL 11 STEARYL ETHER
| Company | Ingredient | NDC |
|---|---|---|
| LEO Pharma Inc | calcipotriene and betamethasone dipropionate | 50222-227 |
| LEO Pharma Inc | calcipotriene and betamethasone dipropionate | 50222-302 |
| Prasco Laboratories | calcipotriene and betamethasone dipropionate | 66993-938 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing POLYPROPYLENE GLYCOL 11 STEARYL ETHER
Excipient focus: PPG-11 STEARYL ETHER
calcipotriene and betamethasone dipropionate drug variants containing PPG-11 STEARYL ETHER
calcipotriene and betamethasone dipropionate drug variants not containing PPG-11 STEARYL ETHER
Excipient focus: SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
calcipotriene and betamethasone dipropionate drug variants containing SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
Excipient focus: SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
calcipotriene and betamethasone dipropionate drug variants containing SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
Excipient focus: TROLAMINE
calcipotriene and betamethasone dipropionate drug variants containing TROLAMINE
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing TROLAMINE
Excipient focus: WATER
calcipotriene and betamethasone dipropionate drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| MC2 Therapeutics Ltd | calcipotriene and betamethasone dipropionate | 73499-001 |
| >Company | >Ingredient | >NDC |
calcipotriene and betamethasone dipropionate drug variants not containing WATER
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
